Moderna Says FDA Will Review Flu Shot Submission -- Market Talk
Dow Jones
Feb 18
0859 ET - Moderna says that the Food and Drug Administration will now review the company's flu-shot submission, marking a pivot from last week when it had refused to review the application. Moderna says it had a meeting with the FDA and proposed a regulatory pathway based on age, seeking full approval for adults 50 to 64 years of age and accelerated approval for adults 65 and older. The FDA has accepted the application for review and set a target review date of Aug. 5. That would make the shot available for U.S. adults 50 years of age and older for the 2026/2027 flu season. Shares jump 8% premarket. (nicholas.miller@wsj.com)
(END) Dow Jones Newswires
February 18, 2026 09:00 ET (14:00 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.